A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

Inclusion Criteria

• •Have a clinical diagnosis of SLE at least 24 weeks prior to screening.
• •Have documentation of having met at least 4 of 11 Revised Criteria for Classification of Systemic Lupus Erythematosus according to the 1997 Update of the 1982 American College of Rheumatology (ACR) criteria for classification of SLE prior to randomization.
• •Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive anti-double-stranded deoxyribonucleic acid (dsDNA), and/or a positive anti-Smith (anti-Sm) as assessed by a central laboratory during screening.
• •Have a total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥6 during screening.
• •Have a clinical SLEDAI-2K score ≥4 at randomization.
• •Have at least 1 British Isles Lupus Assessment Group (BILAG) A score or 2 BILAG B scores during screening.
• •Are receiving at least one of the following standard of care medications for SLE:
• •* A single antimalarial at a stable dose for at least 8 weeks prior to screening
• •* A single immunosuppressant at a stable dose for at least 8 weeks prior to screening
• •* An oral corticosteroid, initiated at least 4 weeks prior to screening, at a stable dose ≤40 milligrams/day prednisone (or equivalent) for at least 2 weeks prior to screening. If the participant is not receiving an antimalarial or immunosuppressant, the dose of corticosteroid must be ≥7.5 milligrams/day prednisone (or equivalent)